FOLINATE TABLETS 25mg "OHARA" (ホリナート錠25mg「オーハラ」)

Country: Japan

Language: English

Source: すりの適正使用協議会 RAD-AR Council, Japan

Active ingredient:

Folinate

Available from:

OHARA Pharmaceutical Co.,Ltd.

INN (International Name):

Folinate

Pharmaceutical form:

white tablet, diameter: 8.1 mm, thickness: 3.4 mm

Product summary:

Print on wrapping: ホリナート25 mg「オーハラ」, 食事の前後１時間をさけて服用する, Folinate25 mg「OHARA」

Patient Information leaflet

Drug Information Sheet("Kusuri-no-Shiori")
Internal
Revised: 06/2017
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
FOLINATE TABLETS 25MG "OHARA"
ACTIVE INGREDIENT:
Folinate
DOSAGE FORM:
white tablet, diameter: 8.1 mm, thickness: 3.4 mm
IMPRINT OR PRINT ON WRAPPING:
ホリナート 25 mg「オーハラ」, 食事の前後１時間
をさけて服用する, Folinate25 mg「OHARA」
EFFECTS OF THIS MEDICINE
This medicine is a reduced folic acid formulation with no antitumor
effect in itself. However, it
enhances the antitumor effects of the anti-cancer medicine
tegafur/uracil when used
concomitantly with the combined medicine (folinate/tegafur/uracil
therapy). This therapy is
expected to relieve symptoms through reduction in the size of cancer
(tumor).
It is usually used for colorectal cancer.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have bone marrow suppression (decrease in white blood cell
count, etc.), diarrhea,
infections, renal disorder, gastrointestinal ulcer/bleeding, diabetes
mellitus or varicella
(chickenpox).
If you have or have a history of liver disorder or heart disease.
If you are currently receiving radiotherapy.
If you have been treated with anti-cancer medicines before.
If you are taking a tegafur/gimeracil/oteracil potassium combined
medicine or have taken this
combined medicine within the last 7 days.
・If you are pregnant, possibly pregnant or breastfeeding.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
di